Lido Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Lido Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,333	Closed	-$213K	–	1749
2025 Q1	$213K	Buy	3,333 +86	+3%	+$9.05K	﹤0.01%	1360
2024 Q4	$395K	Buy	3,247 +18	+0.6%	+$2.21K	﹤0.01%	1086
2024 Q3	$403K	Sell	3,229 -3	-0.1%	-$415	﹤0.01%	1034
2024 Q2	$511K	Buy	+3,232	New	+$415K	﹤0.01%	920
2021 Q1	–	Sell	-1,370	Closed	-$233K	–	894
2020 Q4	$233K	Buy	+1,370	New	+$203K	﹤0.01%	709

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Lido Advisors's SRPT Position: Q2 2025 in Review

Lido Advisors sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 3,333 shares — an estimated $213K sold.

Lido Advisors first reported a position in SRPT in Q4 2020 and held it in 5 quarters. The position peaked at $511K in Q2 2024. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

Lido Advisors reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
Lido Advisors sold 3,333 Sarepta Therapeutics shares in Q2 2025, an estimated $213K.
Lido Advisors first reported a position in Sarepta Therapeutics in Q4 2020 and held it in 5 quarters.
Lido Advisors's Sarepta Therapeutics position peaked at $511K in Q2 2024.
362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Lido Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.